Elderly patients are often under-represented in clinical trials and therefore may not receive the necessary treatment. Dr Matti Aapro explains that elderly patients should receive immunotherapy under the same circumstances as younger patients. While they may experience more treatment-related toxicity, the benefits can outweigh this, and therefore the side effects just require close management. Dr Aapro explains that the reason for under-representation of elderly patients in clinical trials is often do to strict inclusion criteria, which does not reflect the real-world population of these patients. They may also be more susceptible to adverse events, which could confound the results. There is also the misconception that elderly patients may harbour less immune responsiveness; this is not always true, as elderly patients can sometimes be fitter than their younger counterparts. Ultimately, inclusion should be based on the individual patient, rather than their age.
1. To what extent is immunotherapy currently used in elderly patients? (0:11)
2. Why are elderly patients under-represented in clinical trials? (0:49)
3. What are the other major challenges in identifying elderly patients who may respond to immunotherapy? (2:30)
4. How are age-related changes in the immune system likely to affect the response of elderly patients to immunotherapy? (4:00)
5. What initiatives are ongoing to improve our understanding of the response of elderly people to immunotherapy? (5:36)
Speaker disclosures: Matti Aapro has nothing to disclose in relation to this interview.
Filmed at the European Society for Medical Oncology (ESMO) 2018 Congress, Munich, Germany, 19–23 October 2018.
Share this Video
Related Videos In Immunotherapy
Leisha A Emens, ESMO 2020 – Overall Survival Analysis from IMpassion 130 in Triple-negative Breast Cancer
Prof. Leisha A Emens joins touchONCOLOGY to discuss the final overall survival analysis of the phase III IMpassion 130 study investigating atezolizumab plus nab-paclitaxel versus placebo plus nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer. Prof. Emens explores what we can learn from these findings, as well as the failure of IMpassion […]
IBRAHIM EL HOUSSIENY, EHA 2019 – CAR-T cells and manufacturing (Part 2)
Ibrahim El Houssieny joins us at the EHA annual meeting in Amsterdam to discuss the most important recent therapeutic advances and manufacturing of CAR-T cells. This is part 2 of his interview, part one can be viewed here. Questions 1. How can we mitigate the toxicities associated with CAR-T cell therapy? (0:05) 2. What is […]
IBRAHIM EL HOUSSIENY, EHA 2019 – CAR-T cells and manufacturing (Part 1)
Ibrahim El Houssieny joins us at the EHA annual meeting in Amsterdam to discuss the most important recent therapeutic advances and manufacturing of CAR-T cells. This is part 1 of his interview, part two can be viewed here. Questions 1. What have been the most exciting recent developments in CAR-T cell therapy? (0:05) 2. Which […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!